AtriCure vs Bioventus
Bioventus reported revenue of $568 million in fiscal 2025, about the same as AtriCure's $534 million in fiscal 2025. AtriCure's revenue grew 14.9% in its latest year, and Bioventus' fell 0.9%. AtriCure had an operating margin of -1.8%, against 9.5% at Bioventus. Free cash flow was $48 million at AtriCure and $72 million at Bioventus.
Side by side
| AtriCure | Bioventus | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $534M | $568M |
| Revenue growth | 14.9% | −0.9% |
| Revenue growth a year, last 5 years | 20.9% | 12.1% |
| Gross margin | 75.0% | 68.3% |
| Operating margin | −1.8% | 9.5% |
| Net margin | −2.1% | 4.0% |
| Free cash flow | $48M | $72M |
| Free cash flow margin | 9.0% | 12.7% |
| Return on capital | −1.9% | 11.1% |
| Net debt to EBITDA | −8.9x | 2.5x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.7% | 6.8% |
| Last close | $56.84 | $10.66 |
| P/E at the last close | 189.5× | 13.3× |
| Insider trades, last 12 months | sold $4.4 million | — |
| Piotroski F-score | 7 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AtriCureBioventus
Operating margin
Percent of revenue
AtriCureBioventus
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AtriCureBioventus
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AtriCure and Bioventus pages.